chinese Factory supply Retatrutide CAS204656-20-2 Tirzepatide for Weight Loss

Understanding Tirzepatide

Tirzepatide is a once-weekly glucose-dependent insulin-stimulating polypeptide (GIP, aka: gastric inhibitory polypeptide) receptor and glucagon-like peptide-1 (GLP-1) receptor dual agonist developed by Lilly Chemicalbook. Both GIP and GLP-1 are hormones secreted by the gut that promote insulin secretion. tirzepatide combines the effects of two insulin-promoting drugs into a single molecule and represents a new class of drugs for the treatment of type 2 diabetes.

Specifications

Medical uses

Tirzepatide has a similar sequence to semaglutide, and the lys side chain in the sequence has PEG modification, which is the functional group of the polypeptide, and can increase the water solubility of the sequence. The main physiological function of TirzepaChemicalbooktide is glucose-dependent insulin nutrition polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor double agonist, which is being developed for the treatment of type 2 diabetes and has entered the clinical stage.

TIRZEPATIDE AND WEIGHT LOSS
A meta-analysis of 9 clinical studies that covered more than 7,000 subjects with diabetes reported that Tirzepatide may lead to more weight loss than potential GLP-1 agonists such as Semaglutide.[7] The duration of the studies ranged from 8 to 52 weeks, and the subjects achieved 5kg weight loss on average. Moreover, Tirzepatide appeared to exhibit better glycemic control than Semaglutide and insulin. Permana et al. concluded, “Tirzepatide has shown superiority in glycemic control and body weight reduction with a good safety profile in patients with T2D.” Tirzepatide has been suggested to induce weight loss regardless of whether the test subject has diabetes. In a clinical trial with 2,539 obese subjects and at least one weight-related complication (excluding diabetes),Tirzepatide exposure was reported to lead to a dramatic reduction in weight.[8] In 72 weeks of exposure, subjects had at least a 20% reduction in weight or more, compared to only 3% weight loss in the placebo group for the same period.

References

1.Tirzepatide (Mounjaro) for type 2 diabetes. Med Lett Drugs Ther. 2022 Jul 11;64(1654):105-107. [PubMed]

2.Collins L, Costello RA. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jan 13, 2023. Glucagon-like Peptide-1 Receptor Agonists. [PubMed]

3.Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, Rodríguez Á. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022 Feb 08;327(6):534-545. [PMC free article] [PubMed]

4.LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Jun 20, 2022. Tirzepatide. [PubMed]

5.Valenzuela-Vallejo L, Guatibonza-García V, Mantzoros CS. Recent guidelines for Non-Alcoholic Fatty Liver disease (NAFLD)/ Fatty Liver Disease (FLD): Are they already outdated and in need of supplementation? Metabolism. 2022 Nov;136:155248. [PubMed]

6.Sun B, Willard FS, Feng D, Alsina-Fernandez J, Chen Q, Vieth M, Ho JD, Showalter AD, Stutsman C, Ding L, Suter TM, Dunbar JD, Carpenter JW, Mohammed FA, Aihara E, Brown RA, Bueno AB, Emmerson PJ, Moyers JS, Kobilka TS, Coghlan MP, Kobilka BK, Sloop KW. Structural determinants of dual incretin receptor agonism by tirzepatide. Proc Natl Acad Sci U S A. 2022 Mar 29;119(13):e2116506119. [PMC free article] [PubMed]

7.Bucheit J, Ayers J, Pamulapati L, Browning A, Sisson E. A Novel Dual Incretin Agent, Tirzepatide (LY3298176), for the Treatment of Type 2 Diabetes Mellitus and Cardiometabolic Health. J Cardiovasc Pharmacol. 2022 Aug 01;80(2):171-179. [PubMed]

8.Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Jun 20, 2022. Tirzepatide. [PubMed]

9.Farzam K, Jan A. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Dec 27, 2022. Beta Blockers. [PubMed]

10.Trujillo J. Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes. J Clin Pharm Ther. 2020 Sep;45 Suppl 1(Suppl 1):43-60. [PMC free article] [PubMed]